Hookipa Pharma Inc. Stock News

NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi

Hookipa Pharma (NASDAQ:HOOK) was downgraded by equities researchers at UBS Group from a buy rating to a neutral rating in a research report issued on Wednesday, The Fly reports. Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Hookipa Pharma from a sell rating to a hold rating in a [] The post Hookipa Pharma (NASDAQ:HOOK) Cut to Neutral at UBS Group appeared first on ETF Daily News .

Goldman Sachs Group Inc. reduced its holdings in shares of Hookipa Pharma Inc (NASDAQ:HOOK) by 80.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,526 shares of the companys stock after selling 139,452 shares during the quarter. Goldman Sachs Group Inc.s []

NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary are

NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPAs management team will participate in virtual investor meetings and present at The JMP Securities Hematology and Oncology Summit that will be held December 6-7, 2021.

Hookipa Pharma (NASDAQ:HOOK) was downgraded by stock analysts at Morgan Stanley from an overweight rating to an equal weight rating in a research note issued on Friday, Price Targets.com reports. They currently have a $6.00 target price on the stock. Morgan Stanleys price objective suggests a potential upside of 43.88% from the stocks previous close. []

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -12.96% and -26.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi

NEW YORK and VIENNA, Austria., Oct. 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav

Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Key

NEW YORK and VIENNA, Austria, Sept. 15, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav

NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav

Shares of HOOKIPA Pharma (NASDAQ:HOOK) moved higher by 3.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 85.71% over the past year to ($0

NEW YORK and VIENNA, Austria, Aug. 05, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi